Hadden MK[Author] - Search Results

Year	Number of Results
2003	1
2005	3
2006	2
2007	5
2008	4
2009	3
2012	5
2013	7
2014	6
2015	6
2016	5
2017	4
2018	7
2019	7
2020	7
2021	8
2022	3
2023	1
2024	0

1

Medulloblastoma drugs in development: Current leads, trials and drawbacks.

Wen J, Hadden MK. Wen J, et al. Among authors: hadden mk. Eur J Med Chem. 2021 Apr 5;215:113268. doi: 10.1016/j.ejmech.2021.113268. Epub 2021 Feb 8. Eur J Med Chem. 2021. PMID: 33636537 Free PMC article. Review.

2

REV1 Inhibition Enhances Radioresistance and Autophagy.

Ikeh KE, Lamkin EN, Crompton A, Deutsch J, Fisher KJ, Gray M, Argyle DJ, Lim WY, Korzhnev DM, Hadden MK, Hong J, Zhou P, Chatterjee N. Ikeh KE, et al. Among authors: hadden mk. Cancers (Basel). 2021 Oct 21;13(21):5290. doi: 10.3390/cancers13215290. Cancers (Basel). 2021. PMID: 34771454 Free PMC article.

3

HLTF Promotes Fork Reversal, Limiting Replication Stress Resistance and Preventing Multiple Mechanisms of Unrestrained DNA Synthesis.

Bai G, Kermi C, Stoy H, Schiltz CJ, Bacal J, Zaino AM, Hadden MK, Eichman BF, Lopes M, Cimprich KA. Bai G, et al. Among authors: hadden mk. Mol Cell. 2020 Jun 18;78(6):1237-1251.e7. doi: 10.1016/j.molcel.2020.04.031. Epub 2020 May 21. Mol Cell. 2020. PMID: 32442397 Free PMC article.

4

Translesion synthesis inhibitors as a new class of cancer chemotherapeutics.

Patel SM, Dash RC, Hadden MK. Patel SM, et al. Among authors: hadden mk. Expert Opin Investig Drugs. 2021 Jan;30(1):13-24. doi: 10.1080/13543784.2021.1850692. Epub 2020 Dec 3. Expert Opin Investig Drugs. 2021. PMID: 33179552 Free PMC article. Review.

5

Targeting the GLI family of transcription factors for the development of anti-cancer drugs.

Dusek CO, Hadden MK. Dusek CO, et al. Among authors: hadden mk. Expert Opin Drug Discov. 2021 Mar;16(3):289-302. doi: 10.1080/17460441.2021.1832078. Epub 2020 Oct 27. Expert Opin Drug Discov. 2021. PMID: 33006903 Review.

6

Recent Advances in Developmental Signaling Pathway Inhibitors for the Treatment of Cancer.

Hadden MK. Hadden MK. Curr Med Chem. 2015;22(35):4031-2. doi: 10.2174/092986732235151126193822. Curr Med Chem. 2015. PMID: 26630931 No abstract available.

7

Hedgehog and Vitamin D Signaling Pathways in Development and Disease.

Hadden MK. Hadden MK. Vitam Horm. 2016;100:231-53. doi: 10.1016/bs.vh.2015.10.006. Epub 2015 Dec 17. Vitam Horm. 2016. PMID: 26827954 Review.

8

Targeting the Translesion Synthesis Pathway for the Development of Anti-Cancer Chemotherapeutics.

Korzhnev DM, Hadden MK. Korzhnev DM, et al. Among authors: hadden mk. J Med Chem. 2016 Oct 27;59(20):9321-9336. doi: 10.1021/acs.jmedchem.6b00596. Epub 2016 Jul 19. J Med Chem. 2016. PMID: 27362876 Review.

9

Dimeric approaches to anti-cancer chemotherapeutics.

Hadden MK, Blagg BS. Hadden MK, et al. Anticancer Agents Med Chem. 2008 Oct;8(7):807-16. doi: 10.2174/187152008785914743. Anticancer Agents Med Chem. 2008. PMID: 18855582 Free PMC article. Review.

10

Oncoepigenomics: making histone lysine methylation count.

Decarlo D, Hadden MK. Decarlo D, et al. Among authors: hadden mk. Eur J Med Chem. 2012 Oct;56:179-94. doi: 10.1016/j.ejmech.2012.08.010. Epub 2012 Aug 11. Eur J Med Chem. 2012. PMID: 22975593 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

70 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year